Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts
Seeking Alpha ·
Tonix Pharmaceuticals ( TNXP ) and MapLight Therapeutics ( MPLT ) traded higher on Thursday after Raymond James launched their coverage, issuing Strong Buy recommendations, with $26 and $46 per share targets, respectively, citing upcoming catalysts. Regarding Tonix ( TNXP ), analyst Tiago Fauth noted
DYAX Investor Sentiment
Bullish (Long) 36% · Bearish (Short) 64%
400 participants
Related News
- Needham says monday.com is 'at the core' of the AI eating software debate
- First Trust California Municipal High Income ETF declares monthly distribution of $0.1430
- Qualcomm CFO talks Modular acquisition's significance for AI data centers
- Markets embrace 'deflation trade' as falling oil, rising real yields pressure gold, Brooks says
- Rafay Expands Its Elevate AI Infrastructure Ecosystem as Market Shifts from GPU Rental to Token Factory Monetization
- Adobe's deal for Topaz Labs is a positive for its tech stack: RBC